文献速递糖尿病肥胖与代谢综合征

合并症、入院血糖与DPP-4抑制剂对2型糖尿病合并COVID-19患者的影响:意大利伦巴第学术医院病例系列

Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy.
PubMed 文献 · Diabetes Care · 2020-10-06

该单中心病例系列纳入387例COVID-19住院患者,其中90例(23.3%)合并2型糖尿病,其死亡率高于无糖尿病者(42.3% vs 21.7%,P<0.001)。校正年龄和性别后,死亡率风险与高血压、冠心病、慢性肾病、卒中和癌症病史独立相关,而与2型糖尿病本身无关(P=0.170)。在糖尿病患者中,入院血糖、IL-6水平、胰岛素及β受体阻滞剂使用与死亡率升高独立相关,而DPP-4抑制剂使用与死亡风险降低独立相关(aHR 0.13,95%CI 0.02-0.92,P=0.042)。

要点

  • 2型糖尿病合并COVID-19患者死亡率高于无糖尿病者,但校正年龄性别后糖尿病本身并非独立危险因素。
  • 糖尿病患者入院血糖每升高1 mmol/L,死亡风险独立增加(aHR 1.22,95%CI 1.04-1.44)。
  • DPP-4抑制剂使用与糖尿病患者死亡风险显著降低独立相关(aHR 0.13,95%CI 0.02-0.92)。

核心结论

  • 入院血糖水平和降糖药物可能影响2型糖尿病合并COVID-19患者的生存。
  • 校正年龄和性别后,2型糖尿病本身与死亡率无独立关联(P=0.170)。
  • DPP-4抑制剂使用与死亡风险降低独立相关(aHR 0.13,95%CI 0.02-0.92,P=0.042)。

研究设计与样本

  • 单中心病例系列,纳入2020年2月20日至4月9日意大利伦巴第某学术医院387例COVID-19住院患者。
  • 比较无糖尿病与2型糖尿病患者的病史、药物治疗、实验室检查和临床结局。
  • 采用Cox比例风险分析探究与死亡率相关的危险因素。

主要发现

  • 90例(23.3%)合并2型糖尿病,其死亡率为42.3%,无糖尿病者为21.7%(P<0.001)。
  • 校正年龄和性别后,死亡率与高血压(aHR 1.84,95%CI 1.15-2.95,P=0.011)、冠心病(aHR 1.56,95%CI 1.04-2.35,P=0.031)、慢性肾病(aHR 2.07,95%CI 1.27-3.38,P=0.003)、卒中(aHR 2.09,95%CI 1.23-3.55,P=0.006)和癌症(aHR 1.57,95%CI 1.08-2.42,P=0.04)独立相关,与2型糖尿病无关(P=0.170)。
  • 在糖尿病患者中,入院血糖(aHR 1.22,95%CI 1.04-1.44,每mmol/L,P=0.015)和IL-6水平(aHR 2.47,95%CI 1.28-4.78,每1-SD增加,P=0.007)与死亡率升高独立相关。
  • 胰岛素治疗(aHR 3.05,95%CI 1.57-5.95,P=0.001)和β受体阻滞剂(aHR 3.20,95%CI 1.50-6.60,P=0.001)与死亡率升高独立相关。

关键数值与推荐

  • 2型糖尿病合并COVID-19患者死亡率为42.3%,无糖尿病者为21.7%(P<0.001)。
  • 入院血糖每升高1 mmol/L,死亡风险aHR 1.22(95%CI 1.04-1.44,P=0.015)。
  • IL-6每增加1个标准差,死亡风险aHR 2.47(95%CI 1.28-4.78,P=0.007)。
  • DPP-4抑制剂使用与死亡风险降低独立相关,aHR 0.13(95%CI 0.02-0.92,P=0.042)。

临床怎么用

  • 对2型糖尿病合并COVID-19患者应关注入院血糖水平,高血糖与死亡风险增加独立相关。
  • 合并高血压、冠心病、慢性肾病、卒中或癌症病史的COVID-19患者死亡风险更高,需加强监测。
  • DPP-4抑制剂使用与死亡风险降低相关,但需进一步研究验证。
  • 胰岛素和β受体阻滞剂使用与死亡风险升高相关,临床决策需个体化评估。

局限性

  • 单中心病例系列设计,样本量有限,可能存在选择偏倚。
  • 观察性研究,无法确立因果关系。
  • 未报告全部混杂因素的控制情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Diabetes may unfavorably influence the outcome of coronavirus disease 19 (COVID-19), but the determinants of this effect are still poorly understood. In this monocentric study, we aimed at evaluating the impact of type 2 diabetes, comorbidities, plasma glucose levels, and antidiabetes medications on the survival of COVID-19 patients. RESEARCH DESIGN AND METHODS: This was a case series involving 387 COVID-19 patients admitted to a single center in the region of Lombardy, the epicenter of the severe acute respiratory syndrome coronavirus 2 pandemic in Italy, between 20 February and 9 April 2020. Medical history, pharmacological treatments, laboratory findings, and clinical outcomes of patients without diabetes and patients with type 2 diabetes were compared. Cox proportional hazards analysis was applied to investigate risk factors associated with mortality. RESULTS: Our samples included 90 patients (23.3%) with type 2 diabetes, who displayed double the mortality rate of subjects without diabetes (42.3% vs. 21.7%, P < 0.001). In spite of this, after correction for age and sex, risk of mortality was significantly associated with a history of hypertension (adjusted hazard ratio [aHR] 1.84, 95% CI 1.15-2.95; P = 0.011), coronary artery disease (aHR 1.56, 95% CI 1.04-2.35; P = 0.031), chronic kidney disease (aHR 2.07, 95% CI 1.27-3.38; P = 0.003), stroke (aHR 2.09, 95% CI 1.23-3.55; P = 0.006), and cancer (aHR 1.57, 95% CI 1.08-2.42; P = 0.04) but not with type 2 diabetes (P = 0.170). In patients with diabetes, elevated plasma glucose (aHR 1.22, 95% CI 1.04-1.44, per mmol/L; P = 0.015) and IL-6 levels at admission (aHR 2.47, 95% CI 1.28-4.78, per 1-SD increase; P = 0.007) as well as treatment with insulin (aHR 3.05, 95% CI 1.57-5.95; P = 0.001) and β-blockers (aHR 3.20, 95% CI 1.50-6.60; P = 0.001) were independently associated with increased mortality, whereas the use of dipeptidyl peptidase 4 inhibitors was significantly and independently associated with a lower risk of mortality (aHR 0.13, 95% CI 0.02-0.92; P = 0.042). CONCLUSIONS: Plasma glucose levels at admission and antidiabetes drugs may influence the survival of COVID-19 patients affected by type 2 diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Mirani M, Favacchio G, Carrone F, et al. Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy. Diabetes Care. 2020. PMID: 33023989. doi:10.2337/dc20-1340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。